We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Bellus Health (BLU) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Bellus Health one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Bellus Health is one of 1191 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Bellus Health is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for BLU's full-year earnings has moved 1.4% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, BLU has returned 34.3% so far this year. At the same time, Medical stocks have lost an average of 11.5%. This means that Bellus Health is outperforming the sector as a whole this year.
Another stock in the Medical sector, Adherex Technologies Inc. (FENC - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 45%.
The consensus estimate for Adherex Technologies Inc.'s current year EPS has increased 16.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Bellus Health belongs to the Medical - Biomedical and Genetics industry, a group that includes 558 individual stocks and currently sits at #76 in the Zacks Industry Rank. On average, stocks in this group have lost 17.7% this year, meaning that BLU is performing better in terms of year-to-date returns.
Adherex Technologies Inc. however, belongs to the Medical - Drugs industry. Currently, this 224-stock industry is ranked #89. The industry has moved -18.4% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Bellus Health and Adherex Technologies Inc. as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Bellus Health (BLU) Outpaced Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Bellus Health one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Bellus Health is one of 1191 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Bellus Health is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for BLU's full-year earnings has moved 1.4% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, BLU has returned 34.3% so far this year. At the same time, Medical stocks have lost an average of 11.5%. This means that Bellus Health is outperforming the sector as a whole this year.
Another stock in the Medical sector, Adherex Technologies Inc. (FENC - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 45%.
The consensus estimate for Adherex Technologies Inc.'s current year EPS has increased 16.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Bellus Health belongs to the Medical - Biomedical and Genetics industry, a group that includes 558 individual stocks and currently sits at #76 in the Zacks Industry Rank. On average, stocks in this group have lost 17.7% this year, meaning that BLU is performing better in terms of year-to-date returns.
Adherex Technologies Inc. however, belongs to the Medical - Drugs industry. Currently, this 224-stock industry is ranked #89. The industry has moved -18.4% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Bellus Health and Adherex Technologies Inc. as they attempt to continue their solid performance.